THER ADV MED ONCOL 2020 10.1177/1758835920926796
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J

LANCET 2020 10.1016/S0140-6736(20)30230-0
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Galsky1, MD; Arija, JAA; Bamias, A; Davis, ID; De Santis, M; Kikuchi, E; Garcia-del-Muro, X; De Giorgi, U; Mencinger, M; Izumi, K; Panni, S; Gumus, M; Ozguroglu, M; Kalebasty, AR; Park, SH; Alekseev, B; Schutz, FA; Li, JR; Ye, DW; Vogelzang, NJ; Bernhard, S; Tayama, D; Mariathasan, S; Mecke, A; Thastrom, A; Grande, E

Transl Cancer Res 2020 10.21037/tcr-19-1876
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST

Genome Med 2020 10.1186/s13073-020-00741-6
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Lee1, HW; Chung, W; Lee, HO; Jeong, D; Jo, A; Lim, JE; Hong, JH; Nam, DH; Jeong, BC; Park, SH; Joo, KM; Park, WY

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Liu1, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J

INT J MOL SCI 2020 10.3390/ijms21082825
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Kim1, H; Lee, SJ; Lee, IK; Min, SC; Sung, HH; Jeong, BC; Lee, J; Park, SH

TARGET ONCOL 2020 10.1007/s11523-020-00706-0
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CANCERS 2020 10.3390/cancers12040943
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH

JAMA-J AM MED ASSOC 2020 10.1001/jama.2020.1707
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
Tap1, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL

Front Oncol 2020 10.3389/fonc.2020.00314
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM

ESMO OPEN 2020 10.1136/esmoopen-2020-000670
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK

J CLIN ONCOL 2020 10.1200/JCO.19.01638
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis1, ES; Piulats, JM; Gross-Goupil, M; Goh, J; Ojamaa, K; Hoimes, CJ; Vaishampayan, U; Berger, R; Sezer, A; Alanko, T; de Wit, R; Li, CD; Omlin, A; Procopio, G; Fukasawa, S; Tabata, KI; Park, SH; Feyerabend, S; Drake, CG; Wu, HY; Qiu, P; Kim, J; Poehlein, C; de Bono, JS

Genome Med 2020 10.1186/s13073-020-0717-8
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J

J ONCOL 2020 10.1155/2020/4659062
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO

CLIN GENITOURIN CANC 2019 10.1016/j.clgc.2019.07.014
Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors
Shin1, SJ; Kim, T; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI; Kang, M

INT J CANCER 2019 10.1002/ijc.32228
Bridging genomics and phenomics of gastric carcinoma
Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM

GASTRIC CANCER 2019 10.1007/s10120-019-00958-4
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
Kim1, TY; Han, HS; Lee, KW; Zang, DY; Rha, SY; Park, YL; Kim, JS; Lee, KH; Park, SH; Song, EK; Jung, SA; Lee, N; Kim, YH; Cho, JY; Bang, YJ

Front Oncol 2019 10.3389/fonc.2019.01327
Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

ANTICANCER RES 2019 10.21873/anticanres.13785
Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

LANCET ONCOL 2019 10.1016/S1470-2045(19)30412-7
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler1, M; Cho, BC; Sayehli, CM; Navarro, A; Soo, RA; Richly, H; Cassier, PA; Tai, D; Penel, N; Nagoya, L; Park, SH; Schostak, M; Gajate, P; Cathomas, R; Rajagopalan, P; Grevel, J; Bender, S; Boix, O; Nogai, H; Ocker, M; Eflinghaus, P; Joerger, M

CANCER RES TREAT 2019 10.4143/crt.2018.604
Atezolizumab in Patients with Pretreated Urothelial Cancer: A Korean Single-Center, Retrospective Study
Hur1, JY; Kim, Y; Kwon, GY; Kang, M; Sung, HH; Jean, HG; Jeong, BC; Seo, SI; Jean, SS; Lee, HM; Lee, SJ; Park, SH

Transl Cancer Res 2019 10.21037/tcr.2019.09.27
Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

Cancer Med 2019 10.1002/cam4.2446
Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03
Bae1, WK; Lee, HJ; Park, SH; Kim, JH; Kim, HJ; Maeng, CH; Park, I; Sohn, BS; Kim, JA; Lee, KH; Lim, D; Chang, H; Kim, SM; Kim, HY; Song, H; Lim, S; Byun, JH; Jung, HA

NEW ENGL J MED 2019 10.1056/NEJMoa1817323
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot1, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; Burgess, E; Fleming, M; Rezazadeh, A; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Zhong, B; Stuyckens, K; Santiago-Walker, A; De Porre, P; O'Hagan, A; Avadhani, A; Siefker-Radtke, AO

CANCER RES TREAT 2019 10.4143/crt.2018.401
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols
Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

Am J Transl Res 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Cancer 2019 10.7150/jca.30257
High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer
Kim1, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

ONCOLOGY-BASEL 2019 10.1159/000499628
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
Miceli1, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J

BMC UROL 2019 10.1186/s12894-019-0463-7
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer
Yoon1, SE; Kim, Y; Cho, J; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Lee, SJ; Park, SH

J ONCOL 2019 10.1155/2019/8736163
Risk Prediction for Contrast-Induced Nephropathy in Cancer Patients Undergoing Computed Tomography under Preventive Measures
Jeon1, J; Kim, S; Yoo, H; Kim, K; Kim, Y; Park, S; Jang, HR; Kim, DK; Huh, W; Kim, YG; Kim, DJ; Oh, HY; Lee, JE

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

CANCER RES TREAT 2019 10.4143/crt.2018.151
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J Cancer 2019 10.7150/jca.29106
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H

CANCERS 2019 10.3390/cancers11020187
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
van den Boom1, HG; Abu-Hanna, A; ter Veer, E; van Kleef, JJ; Lordick, F; Stahl, M; Ajani, JA; Guimbaud, R; Park, SH; Dutton, SJ; Bang, YJ; Boku, N; Mohammad, NH; Sprangers, MAG; Verhoeven, RHA; Zwinderman, AH; van Oijen, MGH; van Laarhoven, HWM

Oncoimmunology 2019 10.1080/2162402X.2018.1544442
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

OncoTargets and therapy 2019 10.2147/OTT.S187621
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ONCOLOGY-BASEL 2018 10.1159/000491753
Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram
Pietrantonio1, F; Barretta, F; Fanotto, V; Park, SH; Morano, F; Fuca, G; Niger, M; Prisciandaro, M; Silvestris, N; Bergamo, F; Fornaro, L; Bordonaro, R; Rimassa, L; Santini, D; Tomasello, G; Antonuzzo, L; Noventa, S; Avallone, A; Leone, F; Faloppi, L; Di Donato, S; de Braud, F; Lee, J; De Vita, F; Di Bartolomeo, M; Miceli, R; Aprile, G

J Gastric Cancer 2018 10.5230/jgc.2018.18.e34
Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH

RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002
Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

BMC CANCER 2018 10.1186/s12885-018-4995-0
Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO

J UROLOGY 2018 10.1016/j.juro.2018.06.030
Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy
Kang1, M; Park, JY; Jeong, CW; Hwang, EC; Song, C; Hong, SH; Kwak, C; Chung, J; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI

LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2018 10.4143/crt.2017.438
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Choi1, YJ; Kim, HS; Park, SH; Kim, BS; Kim, KH; Lee, HJ; Song, HS; Shin, DY; Lee, HY; Kim, HG; Lee, KH; Lee, JL; Park, KH

ANN ONCOL 2018 10.1093/annonc/mdy264
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Bang1, YJ; Ruiz, EY; Van Cutsem, E; Lee, KW; Wyrwicz, L; Schenker, M; Alsina, M; Ryu, MH; Chung, HC; Evesque, L; Al-Batran, SE; Park, SH; Lichinitser, M; Boku, N; Moehler, MH; Hong, J; Xiong, H; Hallwachs, R; Conti, I; Taieb, J

NAT MED 2018 10.1038/s41591-018-0101-z
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK

J Cancer 2018 10.7150/jca.26068
Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST

J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

BRIT J CANCER 2018 10.1038/s41416-018-0164-0
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Powles1, T; Motzer, RJ; Escudier, B; Par, S; Kollmannsberger, C; Pikiel, J; Gurney, H; Rha, SY; Park, SH; Geertsen, PF; Gross-Goupil, M; Grande, E; Suarez, C; Markby, DW; Arroyo, A; Dean, M; Choueiri, TK; George, D

BMC UROL 2018 10.1186/s12894-018-0380-1
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
Kim1, YS; Kim, K; Kwon, GY; Lee, SJ; Park, SH

J Cancer 2018 10.7150/jca.24948
Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

INT J UROL 2018 10.1111/iju.13574
Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
Kang1, M; Yu, J; Sung, HH; Jeon, HG; Jeong, BC; Park, SH; Jeon, SS; Lee, HM; Choi, HY; Seo, SI

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

ANN ONCOL 2018 10.1093/annonc/mdy055
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Kang1, YK; Ryu, MH; Park, SH; Kim, JG; Kim, JW; Cho, SH; Park, YI; Park, SR; Rha, SY; Kang, MJ; Cho, JY; Kang, SY; Roh, SY; Ryoo, BY; Nam, BH; Jo, YW; Yoon, KE; Oh, SC

ANN ONCOL 2018 10.1093/annonc/mdy034
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients
Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

J Cancer 2018 10.7150/jca.25132
The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO

TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY

CANCER RES TREAT 2018 10.4143/crt.2016.584
Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Jung1, KS; Lee, SJ; Park, SH; Lee, JL; Lee, SH; Lim, JY; Kang, JH; Lee, S; Rha, SY; Lee, KH; Kim, HY; Lim, HY

TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.008
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
Lee1, JY; Kim, K; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Kwon, GY; Kim, KM; Lee, J; Lim, HY; Park, SH

J GYNECOL ONCOL 2018 10.3802/jgo.2018.29.e3
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
Kim1, HJ; Kim, Y; Lee, SJ; Lee, J; Park, SH

ONCOTARGET 2017 10.18632/oncotarget.18182
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
Ahn1, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3445-z
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Sakai1, D; Chung, HC; Oh, DY; Park, SH; Kadowaki, S; Kim, YH; Tsuji, A; Komatsu, Y; Kang, YK; Uenaka, K; Wijayawardana, SR; Wacheck, V; Wang, XJ; Yamamura, A; Doi, T

ONCOTARGET 2017 10.18632/oncotarget.22394
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J

LANCET ONCOL 2017 10.1016/S1470-2045(17)30682-4
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Bang1, YJ; Xu, RH; Chin, K; Lee, KW; Park, SH; Rha, SY; Shen, L; Qin, S; Xu, N; Im, SA; Locker, G; Rowe, P; Shi, XJ; Hodgson, D; Liu, YZ; Boku, N

INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS

ONCOTARGET 2017 10.18632/oncotarget.3750
MerTK is a novel therapeutic target in gastric cancer
Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J

Oncoimmunology 2017 10.1080/2162402X.2017.1356150
Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity
Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM

ONCOLOGIST 2017 10.1634/theoncologist.2017-0020
Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials
Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.19985
Development of mesenchymal subtype gene signature for clinical application in gastric cancer
Lee1, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK

ONCOTARGET 2017 10.18632/oncotarget.20492
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.18168
The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001
Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model
Jang1, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM

BMC UROL 2017 10.1186/s12894-017-0253-z
A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
Kim1, HS; Lee, JY; Lee, SJ; Lim, HY; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Park, SH

J Cancer 2017 10.7150/jca.18286
The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS

CANCER RES TREAT 2017 10.4143/crt.2016.417
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma
Lim1, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM

J Cancer 2017 10.7150/jca.19582
MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.

Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.

Asia Pac J Clin Oncol. 2017 Feb;13(1):61-67. doi: 10.1111/ajco.12465. Epub 2016 Mar 31.
Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma
Lim SH11, Hwang IG2, Ji JH3, Oh SY4, Yi JH5, Lim DH6, Lim HY1, Lee SJ1, Park SH1.

Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362.
Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer
Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Mol Biosyst. 2016 Nov 15;12(12):3611-3621.
Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS
Lee SH11, Jeong S2, Lee J2, Yeo IS3, Oh MJ2, Kim U2, Kim S2, Kim SH1, Park SY4, Kim JH5, Park SH6, Kim JH3, An HJ2.

J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016.
To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.

CANCER RESEARCH AND TREATMENT, OCT 2016, 48(4) :1274-1285, DOI: 10.4143/crt.2015.502
Is There a Role for Adjuvant Therapy in RO Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
Go SI1, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH

Biochem J. 2016 Sep 1;473(17):2603-10. doi: 10.1042/BCJ20160482. Epub 2016 Jun 22.
Critical role of XBP1 in cancer signalling is regulated by PIN1
Chae U11, Park SJ2, Kim B1, Wei S3, Min JS4, Lee JH5, Park SH6, Lee AH7, Lu KP3, Lee DS8, Min SH9.

Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27.
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.

Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4.
A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer
Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.

BMC Urol. 2016 Aug 2;16(1):46. doi: 10.1186/s12894-016-0163-5.
A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim MJ11, Park SH2, Lee JL3, Lee SH4, Lee SJ5, Lim HY5.

J Cancer. 2016 Jul 27;7(12):1711-1715. eCollection 2016.
Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
Lee HY11, Hwang IG2, Park SE2, Kim MJ3, Park SH4, Kang JH5, Kim YS6, Oh SY7, Won YW8, Lee SI9, Ji JH10, Chi KC11.

Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523.
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis
Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.

Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8.
Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL
Lim SH11, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16.
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.

Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12.
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
Kim HK11, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.

Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26.
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma
Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.
Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
Kim ST11, Lee